Drug Trial Radar · NCT01757275
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Last checked: Nov 21, 2026Latest source record: Mar 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239
Actual
Start
Feb 2013
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in
Conditions
- Bleeding Peptic Ulcer
Interventions
Esomeprazole NaDrug
Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
CimetidineDrug
Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
Esomeprazole MgDrug
40 mg tablet once daily for 27 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Clinically Significant Rebleeding Within 72 HoursTime frame: 72 hours
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Ha'er Bing, China
Research Site
Hangzhou, China
Research Site
Jinan, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Shanghai, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.